Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Verisign, Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Verisign, Inc. trades at $303.74 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 2.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Verisign, Inc. pays a 1.09% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Verisign, Inc. for 123 Days on average.
| HALO | VRSN | |
|---|---|---|
Market Cap | $12.58B | $26.92B |
Volume | 2,179,278 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $115.22 | $310.00 |
52-Week Low | $61.63 | $211.49 |
Typical Hold Time | 1 Days | 123 Days |
Enterprise Value | $14.49B | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VeriSign (VRSN) trades at $297.79, up 1.21% today, with a bullish technical signal and strong fundamentals including a 49.77% net income margin. Recent earnings show mixed quarterly beats, while institutional buying and a pending Q3 2026 report highlight investor interest. The stock faces resistance near $299, with support at $296.
Outlook remains positive with a consensus price target of $348, driven by robust cash flow and domain growth, though risks include an antitrust lawsuit and high valuation multiples. The buy-rated stock offers upside potential but requires monitoring of legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
